Dr John Seymour giving Dr Michael Keating plenary award lecture at #SOHO24 Society of Hematologic Oncology (SOHO) First patient ever treated with venetoclax (previously called ABT-199) was in June 2011 in Australia with Dr Seymour. Amazing how this drug has changed the practice of leukemia care,

With the MD Anderson Cancer Center CLL research team at #SOHO24 Society of Hematologic Oncology (SOHO) An amazing group dedicated to the care of patients with CLL 👏👏

Amazing talk about #leukemia with the GOAT Nitin Jain Society of Hematologic Oncology (SOHO) #SOHO2024 MD Anderson Cancer Center looking forward to collaborating with upcoming research and working with you!

Dr Wierda discussing best option for high risk CLL pts - I like this slide as a visual for hypothetical length of time on/off therapy based upon therapeutic sequencing calliecoombs #SOHO24

Watch Naval Daver, MD & Tapan Kadia, MD discuss the latest Acute Myeloid Leukemia #AML updates from #SOHO2024 - to participate, visit: bit.ly/AMLHouston24T x.com/i/broadcasts/1…

Listening to some of my favorite Texans tonight at #SOHO24 #SOHO2024 #CARTcell #mmsm #lymsm #AMLsm #leusm Jason Westin, MD FACP FASCO Larry Anderson,MD,PhD,FACP Naval Daver, M.D. Tapan Kadia

Venetoclax in AML - Naval Daver, M.D. Tapan Kadia #SOHO24 #SOHO2024 #AMLsm #leusm #PrecisionMedicine

KMT2Ar AML - Naval Daver, M.D. Tapan Kadia #SOHO24 #SOHO2024 #AMLsm #leusm #PrecisionMedicine Menin inhibitors #caxtx

CONGRESS | #SOHO2024 William Wierda, MD Anderson Cancer Center, presents post hoc exploratory analysis results of the phase I/II TRANSCEND CLL 004 study evaluating characteristics associated with response to liso-cel in pts with R/R CLL/SLL (n=87). OR and CR rates did not correlate with

CONGRESS | #SOHO2024 William Wierda, MD Anderson Cancer Center, discusses whether continuous therapy is the best option for high-risk pts with CLL. In pts with del(17p)/TP53 mutations, second generation covalent BTK inhibitors (such as ibrutinib) show median PFS of 6+ years, however, are

CONGRESS | #SOHO2024 | Elias Jabbour, MD Anderson Cancer Center shares data of D-D Mini-HCVD-inotuzumab-blinatumomab for the treatment of R/R ALL; concluding with the feasibility of the combination based on safety and efficacy data. Overall 1-year OS 90% vs 66%. #ALLsm #leusm

👉👉👉Wonderful to attend #SOHO24 #SOHO2024 !! Amazing to see its rapid growth ! Dr Fadi Haddad, MD Prof Naveen Pemmaraju, MD Prof Jorge Cortes MD || Society of Hematologic Oncology (SOHO) #leusm #endcancer

Watch this video with Charlie Craddock CBE and Hagop Kantarjian,MD on #AML progress, from the intro of intensive chemotherapy to targeted therapies to transplant. #MedTwitter youtu.be/RBEA0etwdyA

Watch the full discussion between Hagop Kantarjian,MD and Nitin Jain on #CLL, BTK inhibitors, and more during #SOHO2024 on YouTube at buff.ly/3UHEHp3

Mini MDACC reunion at the poster session yesterday #ASH24 Tapan Kadia Fadi Haddad, MD Hannah Goulart Jen Marvin-Peek, MD Caitlin Rausch Nadya Alex Lovell Alex Bazinet

In a study of combined Pirtobrutinib, Venetoclax and Obinutuzumab as a first-line treatment for patients with chronic lymphocytic leukemia (CLL) with a median follow up of nearly a year, no patients have progressed or died, our Nitin Jain reported. Read more:

Updated results from the Phase III COMMANDS trial, presented by our Dr. Guillermo Garcia-Manero at #ASCO25, support luspatercept as the standard of care for anemia in patients with lower-risk myelodysplastic syndromes. Guillermo Garcia-Manero ASCO #EndCancer

Our Dr. Naval Naval Daver, M.D. shared an encouraging safety profile for the first-in-class macrophage checkpoint inhibitor, bexmarilimab, in combination with azacitidine for treatment of higher-risk myelodysplastic syndrome in both the frontline and refractory/relapsed settings.

New data from the CADENZA study shows pivekimab sunirine (PVEK) led to a 70% CR + CRc rate in frontline BPDCN with a manageable safety profile. Presented by Dr. Naveen Pemmarju at #ASCO25. #EndCancer bit.ly/45E62i9 Naveen Pemmaraju, MD

Early results show encouraging efficacy of a novel triplet combo of cladribine, venetoclax, and alternating azacitidine and low-dose cytarabine in patients with higher-risk MDS and CMML, presented by our Dr. Guillermo Montalban-Bravo at #ASCO25. Read more: bit.ly/43AMrN8 ASCO